- Recommendation ID
- TA319/2
- Question
- Further research into whether concomitant dacarbazine enhances the clinical effectiveness of ipilimumab would be encouraged because it could provide information for future treatment strategies, as would more data on the relative effectiveness of ipilimumab when given as a first-line or second-line treatment.
- Any explanatory notes
(if applicable) - It could provide information for future treatment strategies, as would more data on the relative
effectiveness of ipilimumab when given as a first-line or second-line treatment.
Source guidance details
- Comes from guidance
- Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
- Number
- TA319
- Date issued
- July 2014
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |
| Last Reviewed | 07/10/2014 |